

Focused Testing – Is it Possible??

Presented by: James Mullis


Authored by: IPAC-RS Materials Working Group



IPAC-RS OINDP Materials Forum
13-14 Sep 2009 • Philadelphia, PA

1

Why Test Container Closure/Device Materials?



IPAC-RS OINDP Materials Forum
13-14 Sep 2009 • Philadelphia, PA

2

Who is Responsible For This Testing?

SUPPLY CHAIN →

Monomers Antistatics Additives	Polymer, Metal, Elastomer	Components Assembly Complete device	Pharma
INGREDIENT SUPPLIER	MATERIAL SUPPLIER	CONVERTER/ ASSEMBLER	PHARMA
C of A Degradation Profile Information	Composition information C of A	Composition information Extractables profile C of A DMF	Controlled Ext. Study Extractables Leachables L&E Correlation



IPAC-RS OINDP Materials Forum
13-14 Sep 2009 • Philadelphia, PA

3

Material Testing – Regulatory Guidance

Key Regulatory Guidance

- PQRI – Safety Thresholds & Best Practices For Extractables & Leachables in OINDP (Extractables/Leachables)
- Health Canada/EMEA Guidance – Pharmaceutical Quality of Inhalation and Nasal Products (Extractables/Leachables)
- FDA - MDI/DPI Draft Guidance (Inhalation Product Performance & Characterization)
- FDA – Guidance on Inhalation solution, suspension, spray and nasal spray products
- CDRH - Reviewer Guidance for Nebulizers, Metered Dose Inhalers, Spacers and Actuators, (Product Characterization including Leachables)
- FDA - Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics (Packaging Characterization)
- CHMP, CVMP - Guideline for Plastic Immediate Packaging Materials (Packaging Characterization)
- EP 3, USP <381>, <661> (Physicochemical)
- ISO10993, USP<87>, USP<88> (Biocompatibility)



IPAC-RS OINDP Materials Forum
13-14 Sep 2009 • Philadelphia, PA

4

Material Testing – Regulatory Expectations

Items to Specify


- Category of device (Biocompatibility Testing)
- Class of plastic, grade of metal, additives etc
- Critical components (drug contact/mucosal contact)

Testing Expectations

- Controlled Extractions Studies – Material selection, predict likely leachables
- Leachable Registration Studies – Assess patient Total Daily Intake (TDI)
- Routine Control of Materials – ID, Extractables & performance of materials
- Physicochemical – depends on type of material
- Biocompatibility – depends on category of device and may include:
 - Cytotoxicity, (in-vitro)
 - Systemic, Intracutaneous, Sensitisation & Irritation (in-vivo)



Process Map – Plastic Component



Controlled Extraction Studies

What are they.....


Detailed extraction studies incorporating multiple solvent systems, extraction techniques & analytical instrumentation to determine the “worst case” extractable profile, i.e. “worst-case” scenario from a leachables perspective

Extraction Study Variables....

- Sample preparation
- Extraction solvent, temperature and duration
- Extraction technique
- Analytical instrumentation (LC-UV/MS, GC-FID/MS, ICP-MS etc)




Polypropylene Controlled Extraction Study




Hexane Reflux


2-Propanol Reflux



Elastomer Controlled Extraction Study



2-Propanol Sonication




2-Propanol Soxhlet




IPAC-RS OINDP Materials Forum
13-14 Sep 2009 • Philadelphia, PA

9

Polypropylene Controlled Extraction Study



GC-MS 2-Propanol Reflux




HPLC-DAD 2-Propanol Reflux



IPAC-RS OINDP Materials Forum
13-14 Sep 2009 • Philadelphia, PA

10


GC/MS Total Ion Chromatogram, Extractables Profile (top) and Leachables Profile (bottom)



IPAC-RS OINDP Materials Forum
13-14 Sep 2009 • Philadelphia, PA

11


Testing & The Drug Product Development Process



IPAC-RS OINDP Materials Forum
13-14 Sep 2009 • Philadelphia, PA

12

OINDP Supplier & MFR Communication



IPAC-RS OINDP Materials Forum
13-14 Sep 2009 • Philadelphia, PA

13

Discussion Point – What Does Pharma Need and Why?

What....

Materials that meet functional/mechanical requirements

Materials that are safe for patients

Why....

Understanding of compounds in materials that may reach the patient and may have consequences

Material that is used in production is the same chemically as that which was used in the clinic so that there is assurance that the drug/pkg/patient interaction remains unchanged



IPAC-RS OINDP Materials Forum
13-14 Sep 2009 • Philadelphia, PA

14

Discussion Point – Extent & Type of Testing Throughout Supply Chain

Material Suppliers

- Typically testing is functional/mechanical or biocompatibility
- Certifications may be given for compliance to food regulations
- Certificates of analysis or conformance accepted from ingredient suppliers without confirmation testing
- Several concerns regarding chemical testing:
 - Risk of giving customers false impression of the level of potential leachables
 - Concerns around extractables methodology – can a generic method be developed & applied (e.g. what should the supplier test, and what kind of data should the supplier provide)
 - Testing not representative of final component – useful as an initial indication of risk



Discussion Point – Extent & Type of Testing Throughout Supply Chain

Converter/Assemblers

- Perform ID and raw materials testing at incoming
- Accept certificates of analysis/conformance without confirmation testing
- Perform physical and dimensional testing (Other offering upon request)
- May perform extractables testing, but have the following concerns:
 - Test can only monitor material but not really control its change or variability
 - Test may be specific to customer's specifications so that one material may have six different extractables methods performed on it
 - Since finished molded parts may only be tested, there are several components that are molded under similar conditions and are tested individually but have essentially the same extractables profile – this testing appears to be redundant




Discussion Point – Extent & Type of Testing Throughout Supply Chain

Pharma

- Extent of testing done in accordance with diverse regulatory expectations/guidance
- Testing may be confirmation of supplier's results (e.g. biocompatibility)
- Each dosage form/pkg/device combination requires individual treatment due to different compatibilities
- Leachables testing & Tox Safety Assessment
- Controlled extraction and routine extraction are performed and may generate the following concerns:
 - Implications for the Pharma companies of material changes post-approval: discontinuation of materials may force stockpiling to allow time for replacement materials testing that may take several years
 - Compounds may be detected that are above the AET but pose no toxicological concern but will certainly delay production



Can a Common Approach To Testing Be Developed between Suppliers and Pharma?



Discussion Points

- **Extent & type of testing throughout the supply chain**
 - Can a generic extractables method be developed & applied to raw material/molded components across drug products?
- **What information is shared between suppliers & customers?**
 - What business documents need to be in place that would allow the ease of information sharing for critical product attributes?
- **What would it take to get to a focussed testing approach?**
 - What don't we have that we need?
 - What do we have that we don't need?
 - Is it possible to do a test at only one place, the right place/time, in the supply chain?
 - Can safety/extractable profiles be made available for materials that have been in use for a long time?
 - Can tiered testing approaches for materials be done?
 - Does testing upstream eliminate the impact of change downstream?

Discussion Points

- **Life cycle management & legacy products**
 - What do the regulatory authorities want to see?
 - Does demonstrating equivalency do enough?
 - What is the current practice for change management and is it too little or too much?
 - How can change control be better managed?
 - Who needs to be on the team of life cycle management?
 - Is there a better way of screening potential materials for replacement supplies?
 - Is there the "typical" scenario and how is this met?